Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation

Clinical Cancer Research

Volumn 16, Issue 21, 2010, Pages 5260-5268

  Carr, Laurie L ^a   Mankoff, David A ^b   Goulart, Bernardo H ^b,c   Eaton, Keith D ^b,c   Capell, Peter T ^b   Kell, Elizabeth M ^b   Bauman, Julie E ^d   Martins, Renato G ^b,c  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; LOW MOLECULAR WEIGHT HEPARIN; MOTESANIB; SORAFENIB; SUNITINIB; WARFARIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HUMAN; HYPOCALCEMIA; LARYNX EDEMA; LEUKOPENIA; LUNG EMBOLISM; MALE; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; ODYNOPHAGIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SUPRAVENTRICULAR TACHYCARDIA; THYROID CANCER; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; CARCINOMA, MEDULLARY; CELL DIFFERENTIATION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INDOLES; IODINE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PYRROLES; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT FAILURE;

EID: 78049462514     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0994     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2008. CA Cancer J Clin 2008;58:71-96.
2. Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 2007;8:148-56.
3. Jimenez C, Hu MI, Gagel RF. Management of medullary thyroid carcinoma. Endocrinol Metab Clin North Am 2008;37:481-96.
4. 18F]fluoro-2-deoxy-D-glucose-positron emission tomography. J Clin Endocrinol Metab 2006;91:498-505.
5. Iagaru A, Kalinyak JE, McDougall IR. F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med 2007;32:690-5.
6. Chow LQM, Eckhardt S. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884-96.
7. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008;21:s37-43.
8. Komminoth P. The RET proto-oncogene in medullary and papillary thyroid carcinoma: molecular features, pathophysiology and clinical implications. Virchows Arch 1997;431:1-9.
9. Yu XM, Lo CY, Lam AKY. Serum vascular endothelial growth factor C correlates with lymph node metastasis and high-risk tumor profiles in papillary thyroid carcinoma. Ann Surg 2008;247:483-9.
10. Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 2007;29:1338-58.
11. George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumor after imatinib failure. Eur J Cancer 2009;24:1959-68.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
13. 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006;47:1059-66.
14. Sherman S, Wirth L, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359:31-42.
15. Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: prevalence, influence of serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83:1121-7.
16. Weber WA, Ziegler SI, Thodtmann R, et al. Reproducibility of metabolic measurements in malignant tumors using FDG-PET. J Nucl Med 1999;40:1771-7. (Pubitemid 29523568)
17. Gupta-Abramson V, Troxel A, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-9.
18. Kloos R, Ringel M, Knopp M, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-84.
19. Cohen E, Rosen L, Vokes E, et al. Axitinib is an active treatment for all histologic subytpes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708-13.
20. Schlumberger M, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27:3794-801.
21. 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 2009;27:439-45.
22. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm 2009;24:137-44.